Copenhagen, Denmark-based Zealand Pharma A/S licensed exclusive global development and commercialization rights to its lead glucagon/GLP-1 dual agonist drug candidate ZP2929, for the treatment of patients with Type II diabetes and patients with obesity, to Boehringer Ingelheim GmbH, of Ingelheim, Germany.